Acorda Therapeutics Inc (ACOR)

Sector:
HEALTH CARE
Industry:
PHARMACEUTICALS
SIC:
BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)
CEO:
Ronald Cohen
Employees:
120
420 SAW MILL RIVER ROAD, ARDSLEY, NY 10502
914-347-4300

Acorda Therapeutics, Inc. develops and commercializes therapies for neurological disorders in the United States. The company markets Ampyra (dalfampridine), an oral drug to improve walking in patients with multiple sclerosis (MS) Inbrija for the treatment of OFF periods in Parkinson's disease in Europe.

Data derived from most recent annual or quarterly report
Market Cap 13.873 Million Shares Outstanding24.338 Million Avg 30-day Volume 175.546 Thousand
P/E Ratio0.0 Dividend Yield0.0 EPS-0.57
Price to Revenue0.1967 Debt to Equity1.1949 EBITDA-28.815 Million
Price to Book Value0.168 Operating Margin-61.23610000000001 Enterprise Value146.949 Million
Current Ratio1.891 EPS Growth0.205 Quick Ratio1.159
1 Yr BETA 1.3515 52-week High/Low 1.82 / 0.26 Profit Margin-80.5402
Operating Cash Flow Growth32.2231 Altman Z-Score-2.7877 Free Cash Flow to Firm 62.069 Million
View SEC Filings from ACOR instead.

View recent insider trading info

Acorda Therapeutics Inc YCharts
Yahoo! Finance finviz
SEC Web Site SEC DEF 14A Filings

Funds Holding ACOR (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
Click for Additional Filters
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding ACOR

Download CSV

Active Schedule 13D and 13G filings

Please sign in first

Recent Filings

Financial Reporting

Ownership

  • 4: filed on 2023-03-20 by COHEN RON
  • 4: filed on 2023-01-04 by VARIAN JOHN
  • 4: filed on 2022-09-07 by SABELLA LAUREN M
  • 4: filed on 2022-09-07 by CLEM KERRY M
  • 4: filed on 2022-06-14 by RANDALL LORIN
  • 4: filed on 2022-06-14 by PANEM SANDRA PHD
  • 4: filed on 2022-06-14 by KELLEY JOHN P
  • 4: filed on 2022-06-14 by JENSEN PEDER
  • 4: filed on 2022-03-21 by COHEN RON
  • 3: filed on 2022-01-05 by VARIAN JOHN

    • Events (8k)

  • 8-K: filed on 2023-03-17:
    Item 8.01: Other Events
  • 8-K: filed on 2023-03-09:
    Item 2.02: Results of Operations and Financial Condition
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2023-02-15:
    Item 3.01: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2023-01-05:
    Item 1.01: Entry into a Material Definitive Agreement
    Item 1.02: Termination of a Material Definitive Agreement
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-12-23:
    Item 7.01: Regulation FD Disclosure
  • 8-K: filed on 2022-12-22:
    Item 7.01: Regulation FD Disclosure
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-12-21:
    Item 3.01: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-12-05:
    Item 8.01: Other Events
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-11-14:
    Item 5.07: Submission of Matters to a Vote of Security Holders
    Item 8.01: Other Events
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-11-04:
    Item 5.07: Submission of Matters to a Vote of Security Holders
    Item 8.01: Other Events
    Item 9.01: Financial Statements and Exhibits

    • Proposed Sales (Form 144)

    Proxy

    Prospectus

    All

    Open Market Buys/Sells Last 60 Days

    Open Market Buys (P)

    20.2 Thousand total shares from 2 transactions

    Open Market Sells (S)

    none

    Exercise Derivative Conversion (M)

    none

    Current/Former Insiders

    Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

    COHEN RON PRESIDENT AND CEO

    • Officer
    • Director
    		 149,757 2023-03-16 1

    VARIAN JOHN

    • Director
    		 4,712 2023-01-01 1

    SABELLA LAUREN M CHIEF OPERATING OFFICER

    • Officer
    		 10,710 2022-09-03 1

    CLEM KERRY M CHIEF COMMERCIAL OFFICER

    • Officer
    		 10,083 2022-09-03 1

    PANEM SANDRA PHD

    • Director
    		 10,000 2022-06-10 1

    KELLEY JOHN P

    • Director
    		 10,000 2022-06-10 1

    RANDALL LORIN

    • Director
    		 10,000 2022-06-10 1

    JENSEN PEDER

    • Director
    		 10,000 2022-06-10 1

    BELLOFF NEIL S. GENERAL COUNSEL

    • Officer
    		 0 2021-11-08 0

    GESSER MICHAEL A CHIEF FINANCIAL OFFICER

    • Officer
    		 0 2021-11-08 0

    MORALES ROBERT INTERIM PAO & PFO

    • Officer
    		 4,423 2021-09-03 0

    GREENE BARRY E

    • Director
    		 10,000 2021-06-02 0

    STRADER CATHERINE D.

    • Director
    		 10,000 2021-06-02 0

    BLANK BURKHARD CMO AND HEAD OF R&D

    • Officer
    		 18,527 2021-03-03 0

    LAWRENCE DAVID CHIEF, BUS. OPS & PAO

    • Officer
    		 13,811 2020-12-01 0

    RAUSCHER STEVEN M

    • Director
    		 0 2020-06-15 0

    WASMAN JANE PRESIDENT, INTL AND GC

    • Officer
    		 117,420 2019-12-02 0

    HINDMAN ANDREW A. CHIEF BUSINESS OFFICER

    • Officer
    		 15,639 2019-03-08 0

    SCOPIA CAPITAL MANAGEMENT LP

    SCOPIA MANAGEMENT, INC.

    SIROVICH MATTHEW

    MINDICH JEREMY

    • 10% Owner
    		 No longer subject to file 2019-01-30 0

    SMITH IAN F

    • Director
    		 0 2018-06-27 0

    BATYCKY RICHARD P. CHIEF TECH. OFF. & SITE HEAD

    • Officer
    		 55,513 2018-02-22 0

    BLIGHT ANDREW CHIEF SCIENTIFIC OFFICER

    • Officer
    		 78,594 2017-03-01 0

    ROGERS MICHAEL W CHIEF FINANCIAL OFFICER

    • Officer
    		 0 2016-05-11 0

    CARRAZANA ENRIQUE J. CHIEF MEDICAL OFFICER

    • Officer
    		 32,148 2015-12-01 0

    WESSEL THOMAS CHIEF MEDICAL OFFICER

    • Officer
    		 36,350 2011-03-03 0

    YOUNG WISE

    • Director
    		 17,307 2010-06-09 0

    PHILLIPS BARCLAY A

    • Director
    		 308,801 2008-06-13 0

    RIDGEBACK CAPITAL INVESTMENTS LTD.

    RIDGEBACK CAPITAL MANAGEMENT LLC

    HOLMAN WAYNE GEORGE

    • 10% Owner
    		 No longer subject to file 2008-01-14 0

    FISHER MARY CHIEF OPERATING OFFICER

    • Officer
    		 57,230 2007-07-02 0

    PINNEY MARK R E

    • Director
    		 1 2006-11-13 0

    FLEMING STANDISH

    • Director
    		 2,041,172 2006-02-15 0

    FRIEDMAN JOHN H

    • Director
    		 1,769,805 2006-02-15 0

    STEINMETZ MICHAEL

    • Director
    		 5,251,838 2006-02-15 0

    BB BIOVENTURES L P

    BAB BIO VENTURES LLP

    BAB BIO VENTURES NV

    MPM ASSET MANAGEMENT INVESTORS 1998 LLC

    MPM BIOVENTURES PARALLEL FUND L P

    MPM BIOVENTURES I LP

    MPM BIO VENTURES I LLC

    GADICKE ANSBERT

    EVNIN LUKE

    • 10% Owner
    		 0 2006-02-09 0

    Insider Transactions Last 60 Days

    Reporting Owners Filing Date Trans Date Trans Code Shares Share Price Acquired
    Disposed    		 Shares Owned after D/I 10b5 Perf 1d* Perf 5d* Perf 1m* Max Gain Max Gain Days Max Loss Max Loss Days

    COHEN RON - Director - Officer PRESIDENT AND CEO

    		2023-03-20 16:29:58 -0400 2023-03-17 P 10,000 $0.65 a 149,757 direct -3.252 0.0 1 -3.252 2

    COHEN RON - Director - Officer PRESIDENT AND CEO

    		2023-03-20 16:29:58 -0400 2023-03-16 P 10,156 $0.60 a 139,757 direct -3.252 0.0 1 -3.252 2

    * -

    Transaction Code Definitions
    Code Definition
    A Grant, award or other acquisition pursuant to Rule 16b-3(d)
    C Conversion of derivative security
    D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
    E Expiration of short derivative position
    F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
    G Bona fide gift
    H Expiration (or cancellation) of long derivative position with value received
    I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
    J Other acquisition or disposition
    L Small acquisition under Rule 16a-6
    M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
    O Exercise of out-of-the-money derivative security
    P Open market or private purchase of non-derivative or derivative security
    S Open market or private sale of non-derivative or derivative security
    U Disposition pursuant to a tender of shares in a change of control transaction
    W Acquisition or disposition by will or the laws of descent and distribution
    X Exercise of in-the-money or at-the-money derivative security
    Z Deposit into or withdrawal from voting trust

    IBR Securities Loan Availability

    Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers

    Security Date/Time Rebate Rate Fee Rate Shares Available
    ACORDA THERAPEUTICS INC ACOR 2023-03-24 15:45:03 UTC -21.1574 25.9774 250000
    ACORDA THERAPEUTICS INC ACOR 2023-03-24 15:15:03 UTC -21.1574 25.9774 250000
    ACORDA THERAPEUTICS INC ACOR 2023-03-24 14:45:03 UTC -21.4074 25.9774 250000
    ACORDA THERAPEUTICS INC ACOR 2023-03-24 14:15:03 UTC -21.4074 25.9774 250000
    ACORDA THERAPEUTICS INC ACOR 2023-03-24 13:45:03 UTC -21.4074 25.9774 250000
    ACORDA THERAPEUTICS INC ACOR 2023-03-24 13:15:04 UTC -21.4074 25.9774 250000
    ACORDA THERAPEUTICS INC ACOR 2023-03-24 12:45:03 UTC -21.4074 25.9774 250000
    ACORDA THERAPEUTICS INC ACOR 2023-03-23 22:15:04 UTC -21.4074 25.9774 300000
    ACORDA THERAPEUTICS INC ACOR 2023-03-23 21:45:04 UTC -21.4074 25.9774 300000
    ACORDA THERAPEUTICS INC ACOR 2023-03-23 21:15:04 UTC -21.4074 25.9774 300000
    ACORDA THERAPEUTICS INC ACOR 2023-03-23 20:45:03 UTC -21.4074 25.9774 300000
    ACORDA THERAPEUTICS INC ACOR 2023-03-23 20:15:03 UTC -21.4074 25.9774 300000
    ACORDA THERAPEUTICS INC ACOR 2023-03-23 19:45:03 UTC -21.4074 25.9774 300000
    ACORDA THERAPEUTICS INC ACOR 2023-03-23 19:15:03 UTC -21.4074 25.9774 300000
    ACORDA THERAPEUTICS INC ACOR 2023-03-23 18:45:04 UTC -21.4074 25.9774 300000
    ACORDA THERAPEUTICS INC ACOR 2023-03-23 18:15:03 UTC -21.4074 25.9774 300000
    ACORDA THERAPEUTICS INC ACOR 2023-03-23 17:45:03 UTC -21.4074 25.9774 300000
    ACORDA THERAPEUTICS INC ACOR 2023-03-23 17:15:03 UTC -21.4074 25.9774 300000
    ACORDA THERAPEUTICS INC ACOR 2023-03-23 16:45:04 UTC -21.4074 25.9774 400000
    ACORDA THERAPEUTICS INC ACOR 2023-03-23 16:15:03 UTC -21.4074 25.9774 400000

    Current Active Short Positions

    Holder Issuer Net Short Position Position Date Origin
    FundVantage Trust- Gotham Enhanced Index Plus Fund ACOR -46.0 shares, $-42.9 2020-03-31 N-PORT
    FundVantage Trust- Gotham Index Plus All-Cap Fund ACOR -76.0 shares, $-70.88 2020-03-31 N-PORT

    No recent transactions

    *** To see all congressional transactions (since 2022) for this stock, please use the congressional transaction search page***

    Elevate your investments